Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease.
Based on pleitropic effects of GLP-1 agonists as a drug class, the results are not surprising and serve as a welcome addition to the armamentarium of ever increasing diabetic kidney disease drugs
Comments